Navigation Links
Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
Date:8/5/2008

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, will announce financial results for its second quarter ended June 30, 2008, on Thursday, August 7, 2008, after the markets close. The announcement will be followed by a live webcast and conference call at 2:00 p.m. Pacific Time.

Orexigen management will host the call and webcast to discuss results for the second quarter ended June 30, 2008, and recent business highlights. The live call may be accessed by phone by calling (800) 860-2442 (domestic) or (412) 858-4600 (international). The webcast can be accessed live on the investor relations section of the Company's Web site at http://www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM), which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
3. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
4. CV Therapeutics Reports 2008 Second Quarter Financial Results
5. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
6. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
7. Cardinal Health, Prime Therapeutics Sign Primary Distribution Agreement
8. United Therapeutics Reports Second Quarter 2008 Financial Results
9. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
10. Silence Therapeutics Patent Update
11. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , ROCHESTER, Minn. and ... 2015 Baxter Ventures, the venture arm of ... Clinic and Velocity Pharmaceutical Development, LLC ("VPD") today announced ... a unique collaboration model initiated by Baxter Ventures to ... in the areas of immunology, hematology, and oncology. Following ...
(Date:6/1/2015)...   Epic Sciences, Inc. , a private diagnostics ... personalize and advance the treatment and management of cancer, ... under its existing credit facility with Silicon Valley ... capacity of the facility from $5 million to $15 ... to April 1, 2019.  The availability of additional capital ...
(Date:6/1/2015)... 2015 Shire plc (LSE: SHP, ... participating in the Jefferies 2015 Global Healthcare Conference in ... June 2, 2015. Jeff Poulton , Chief Financial ... at 10:00 a.m. ET (3:00 p.m. BST). ... Presentations and Webcasts section of Shire,s Investor website at ...
(Date:6/1/2015)... May 29, 2015 Research and ... of the "2015 Assessments of Leading ... and Recent Market Entrants" report to ... report from VPGMarketResearch.com provides insightful profiles of ... entrants. The report presents strategic ...
Breaking Biology Technology:Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants 2
... Biotechnology, Inc. (OTC: CSBR) ("Champions") announced today the ... Inc. in which Champions will conduct low passage ... an inhibitor of mutant B-Raf, and CEP-37440, a ... determine the activity or response in potential clinical ...
... Laboratory, Inc. (HDL, Inc.) and BG Medicine, Inc. (Nasdaq: ... Inc. will offer galectin-3 testing services based on the BG ... Test was recently cleared by the FDA as an aid ... Elevated galectin-3 levels are associated with an inherently progressive form ...
... The Ontario Institute for Cancer Research (OICR) ... accelerate commercialization of a potentially revolutionary high-throughput screening ... The technology, Smart Well Plate™, developed at the ... utilizes digital microfluidics (DMF), a technique that allows ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 4Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs 2Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs 3
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... expressions of different types are detected in a crowd ... faces are a priority for visual processing ?particularly for ... of the Massachusetts Institute of Technology and Jason Mattingley ... the June 6th issue of Current Biology. , ...
... demonstrated that learning about the appearance of their parents ... parental traits, rather than traits that more exactly match ... help drive the evolution of exaggerated traits and strong ... and other animals. The findings are reported by Carel ...
... of Michigan Kellogg Eye Center have gained new insight into ... itself to a specific role. They have observed a small ... to play a particular role, but has not yet begun ... vantage point for understanding how a healthy visual system develops. ...
Cached Biology News:Zebra finch males prefer females with exaggerated maternal traits 2Study provides first look at the 'birth' of a retina cell 2Study provides first look at the 'birth' of a retina cell 3
Permeabilization Solution, 5X...
PCR purification kit, 100 preps...
Oxidative Stress-Inducible Protein Tyrosine Phosphatase...
Raised to 5-HIAA coupled to BSA with paraformaldehyde....
Biology Products: